Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Dow
Mallinckrodt
Colorcon
McKinsey

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR ESTRAMUSTINE PHOSPHATE SODIUM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Estramustine Phosphate Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002721 ↗ Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer Completed University of New Mexico Phase 1 1995-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic recurrent prostate cancer that does not respond to hormone therapy.
NCT00002775 ↗ Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer Unknown status Herbert Irving Comprehensive Cancer Center Phase 1/Phase 2 1998-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel and estramustine in treating patients who have metastatic prostate cancer.
NCT00002855 ↗ Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Completed National Cancer Institute (NCI) Phase 3 1996-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002855 ↗ Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Completed M.D. Anderson Cancer Center Phase 3 1996-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Estramustine Phosphate Sodium

Condition Name

Condition Name for Estramustine Phosphate Sodium
Intervention Trials
Prostate Cancer 26
Lymphoma 2
Adenocarcinoma of the Prostate 2
Kidney Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Estramustine Phosphate Sodium
Intervention Trials
Prostatic Neoplasms 27
Adenocarcinoma 2
Lymphoma 2
Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Estramustine Phosphate Sodium

Trials by Country

Trials by Country for Estramustine Phosphate Sodium
Location Trials
United States 219
Canada 3
Puerto Rico 2
Australia 1
South Africa 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Estramustine Phosphate Sodium
Location Trials
New York 16
Illinois 10
Ohio 8
New Jersey 8
Michigan 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Estramustine Phosphate Sodium

Clinical Trial Phase

Clinical Trial Phase for Estramustine Phosphate Sodium
Clinical Trial Phase Trials
Phase 3 6
Phase 2 17
Phase 1/Phase 2 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Estramustine Phosphate Sodium
Clinical Trial Phase Trials
Completed 23
Unknown status 4
Terminated 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Estramustine Phosphate Sodium

Sponsor Name

Sponsor Name for Estramustine Phosphate Sodium
Sponsor Trials
National Cancer Institute (NCI) 21
Eastern Cooperative Oncology Group 4
Memorial Sloan Kettering Cancer Center 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Estramustine Phosphate Sodium
Sponsor Trials
Other 39
NIH 22
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.